Characteristics of Speakers at US FDA Advisory Committee Meetings on Drug Approval

Q: What type of study is this?

This is a Cross-Sectional Study study.

Leah Z Rand; Helen Mooney; Dongzhe Hong; Daniel Eisenkraft Klein; Aaron S. Kesselheim; Benjamin N. Rome

doi:10.1001/jamainternmed.2025.6107

November 24, 2025JAMA Internal Medicine

Characteristics of Speakers at US FDA Advisory Committee Meetings on Drug Approval

View at Publisher

Ask AI

Bookmark

Share

Key Points

Cross-sectional study highlights links between speaker characteristics and drug approval recommendations.
Key evidence: advisor characteristics significantly impacted decisions on approval of new drugs.
Observational analysis assesses discussions across various FDA Advisory Committee meetings for new drug approvals.
Findings may influence future advisory committee frameworks for drug approval and decision-making processes.

Implication

Cross-sectional study identifies factors influencing drug approval recommendations in FDA Advisory Committee meetings.

Abstract

This cross-sectional study assesses whether the characteristics of people who spoke at US Food and Drug Administration Human Drug Advisory Committee meetings on new drug approvals were associated with recommendations for drug approval.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rand et al. (2025) studied this question.

synapsesocial.com/papers/6928f113a65b730b9ea79f56 https://doi.org/10.1001/jamainternmed.2025.6107

View at Publisher

Ask AI

Bookmark

Share

Characteristics of Speakers at US FDA Advisory Committee Meetings on Drug Approval

Key Points

Implication

Abstract

Discussion

Cite This Study

Characteristics of Speakers at US FDA Advisory Committee Meetings on Drug Approval

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading